Life Span and Population Health

Determining optimal timing of birth for women with chronic or gestational hypertension at term: The WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial (2024)
Journal Article
Magee, L. A., Kirkham, K., Tohill, S., Gkini, E., Moakes, C. A., Dorling, J., Green, M., Hutcheon, J. A., Javed, M., Kigozi, J., Mol, B. W., Singer, J., Hardy, P., Stubbs, C., Thornton, J. G., von Dadelszen, P., & WILL Trial Study Group. (2024). Determining optimal timing of birth for women with chronic or gestational hypertension at term: The WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial. PLoS Medicine, 21(11), Article e1004481. https://doi.org/10.1371/journal.pmed.1004481

Background Chronic or gestational hypertension complicates approximately 7% of pregnancies, half of which reach 37 weeks’ gestation. Early term birth (at 37 to 38 weeks) may reduce maternal complications, cesareans, stillbirths, and costs but may inc... Read More about Determining optimal timing of birth for women with chronic or gestational hypertension at term: The WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial.

The acceptability of implementation of group B Streptococcus testing: Perspectives from women and health professionals in the GBS3 trial: A qualitative study (2024)
Journal Article
Constantinou, G., Ayers, S., Mitchell, E. J., Walker, K. F., Downe, S., Jones, A.-M., Moore, S., & Daniels, J. P. (2024). The acceptability of implementation of group B Streptococcus testing: Perspectives from women and health professionals in the GBS3 trial: A qualitative study. Women and Birth, 37(6), Article 101832. https://doi.org/10.1016/j.wombi.2024.101832

Objective: To determine the acceptability of different methods of routine testing for group B Streptococcus (GBS) colonisation to pregnant women and health care professionals (HCPs), and to examine barriers and facilitators to their implementation. D... Read More about The acceptability of implementation of group B Streptococcus testing: Perspectives from women and health professionals in the GBS3 trial: A qualitative study.

Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women (IVON-PP): protocol for an open-label randomised controlled type 1 hybrid effectiveness-implementation trial (2024)
Journal Article
Afolabi, B. B., Adaramoye, V. O., Adeyemo, T. A., Balogun, M., Mitchell, E. J., Walker, K., Akinajo, O. R., Abioye, I. A., Banke-Thomas, A., Babah, O. A., Chieme, C. F., Oshodi, Y., Quao, R., Eboreime, E. A., & Ogunsola, F. (2024). Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women (IVON-PP): protocol for an open-label randomised controlled type 1 hybrid effectiveness-implementation trial. BMJ Open, 14(8), Article e086553. https://doi.org/10.1136/bmjopen-2024-086553

Introduction Postpartum anaemia is often caused by iron deficiency with onset during the antepartum period and can be exacerbated by excessive blood loss at birth. Its prevalence is estimated as 50–80% in low-income and middle-income countries. It po... Read More about Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women (IVON-PP): protocol for an open-label randomised controlled type 1 hybrid effectiveness-implementation trial.

Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up (2024)
Journal Article
Van Der Windt, L., Klumper, J., Van, E. V. J., Stirum, L., Van 't Hooft, J., Van Wely, M., Van Wassenaer-Leemhuis, A. G., Pajkrt, E., Oudijk, M. A., & Group, S. (2024). Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. BMJ Open, 14(7),

Introduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcome... Read More about Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up.

The acceptability of group B streptococcal bacteria (GBS) testing to women, including self-swabbing procedures: A qualitative study (2024)
Journal Article
Constantinou, G., Ayers, S., Mitchell, E. J., Moore, S., Jones, A.-M., Downe, S., Walker, K. F., & Daniels, J. (2024). The acceptability of group B streptococcal bacteria (GBS) testing to women, including self-swabbing procedures: A qualitative study. Midwifery, 135, Article 104063. https://doi.org/10.1016/j.midw.2024.104063

Background
Group B streptococcus (GBS) is a bacterium carried by 20–25 % of pregnant women in the UK, which can be transmitted from pregnant women to their babies at the time of birth. Women can be tested for GBS in pregnancy using a vaginal-rectal... Read More about The acceptability of group B streptococcal bacteria (GBS) testing to women, including self-swabbing procedures: A qualitative study.

GBS vaccines in the UK: a round table discussion [version 1; peer review: 4 approved] (2024)
Journal Article
Thorn, N., Guy, R. L., Karampatsas, K., Powell, M., Walker, K. F., Plumb, J., Khalil, A., Greening, V., Eccleston, E., Trotter, C., Andrews, N., Rush, L., Sharkey, C., Wallis, L., Heath, P., & Le Doare, K. (2024). GBS vaccines in the UK: a round table discussion [version 1; peer review: 4 approved]. F1000Research, 13, Article 519. https://doi.org/10.12688/f1000research.147555.1

Background
Group B streptococcus (GBS) remains a leading cause of infant sepsis, meningitis and death despite intrapartum antibiotic prophylaxis. A vaccine is urgently required, and two candidates are in advanced clinical trials. For successful GBS... Read More about GBS vaccines in the UK: a round table discussion [version 1; peer review: 4 approved].

Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis (2024)
Journal Article
Fernández-García, S., Del Campo-Albendea, L., Sambamoorthi, D., Sheikh, J., Lau, K., Osei-Lah, N., Ramkumar, A., Naidu, H., Stoney, N., Sundaram, P., Sengupta, P., Mehta, S., Attarde, S., Maddock, S., Manning, M., Meherally, Z., Ansari, K., Lawson, H., Yap, M., Kew, T., …Thangaratinam, S. (2024). Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis. BMJ Global Health, 9(4), Article e014247. https://doi.org/10.1136/bmjgh-2023-014247

Objective
To assess the effects of COVID-19 vaccines in women before or during pregnancy on SARS-CoV-2 infection-related, pregnancy, offspring and reactogenicity outcomes.

Design
Systematic review and meta-analysis.

Data sources
Major databa... Read More about Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis.

Outputs (7)